Literature DB >> 32221994

Composite score for prediction of 30-day orthopedic surgery outcomes.

Ian F Caplan1, Eric Winter1, Gregory Glauser1, Stephen Goodrich2,3, Scott D McClintock3, Eric L Hume4, Neil R Malhotra1,2.   

Abstract

The LACE+ (Length of stay, Acuity of admission, Charlson Comorbidity Index score, and Emergency department visits in the past 6 months) risk-prediction tool has never been tested in an orthopedic surgery population. LACE+ may help physicians more effectively identify and support high-risk orthopedics patients after hospital discharge. LACE+ scores were retrospectively calculated for all consecutive orthopedic surgery patients (n = 18 893) at a multi-center health system over 3 years (2016-2018). Coarsened exact matching was employed to create "matched" study groups with different LACE+ score quartiles (Q1, Q2, Q3, Q4). Outcomes were compared between quartiles. In all, 1444 patients were matched between Q1 and Q4 (n = 2888); 2079 patients between Q2 and Q4 (n = 4158); 3032 patients between Q3 and Q4 (n = 6064). Higher LACE+ scores significantly predicted 30D readmission risk for Q4 vs Q1 and Q4 vs Q3 (P < .001). Larger LACE+ scores also significantly predicted 30D risk of ED visits for Q4 vs Q1, Q4 vs Q2, and Q4 vs Q3 (P < .001). Increased LACE+ score also significantly predicted 30D risk of reoperation for Q4 vs Q1 (P = .018), Q4 vs Q2 (P < .001), and Q4 vs Q3 (P < .001).
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  LACE+ index; coarsened exact matching; discharge predictive tool; orthopedic surgery; reduce readmissions

Mesh:

Year:  2020        PMID: 32221994     DOI: 10.1002/jor.24673

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  1 in total

Review 1.  Compilation and Analysis of Web-Based Orthopedic Personalized Predictive Tools: A Scoping Review.

Authors:  Patrick Curtin; Alexandra Conway; Liu Martin; Eugenia Lin; Prakash Jayakumar; Eric Swart
Journal:  J Pers Med       Date:  2020-11-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.